Sight Sciences Archives - Medical Design Sourcing

Sight Sciences closes $65M credit facility

Sight Sciences (Nasdaq:SGHT) announced that it closed a senior secured credit facility worth up to $65 million.

The credit facility with Hercules Capital includes the immediate draw of $35 million. Menlo Park, California-based Sight Sciences used the proceeds to pay off the principal amount of debt to its previous secured lender.

In addition to the $35 million at closing, the facility includes up to an additional $30 million potentially available. That remains subject to certain conditions agreed upon between Sight Sciences and Hercules Capital.

The facility has a 54-month maturity and an interest-only period of 30 months. That interest-only period can extend to 36 months, subject to the achievement of certain performance milestones.

Sight Sciences develops ophthalmology and optometry devices. Omni, a minimally invasive glaucoma surgery (MIGS) device, reduces IOP to treat adult patients with open-angle glaucoma (OAG). TearCare, which holds FDA 510…

Axonics, Outset lead medtech space on Deloitte’s list of fastest growing companies

Deloitte today released its “North America Technology Fast 500” list of growing companies, including a handful of medtech firms.

The list, which ranking of the fastest-growing North American companies across a range of sectors, included several “Life Sciences” outfits. Immunology company Vir Biotechnology led the way in first place on the list.

Axonics (Nasdaq:AXNX) represented the highest-ranked medical device company at No. 4. According to Deloitte, the company registered 25,401% growth over a three-year period. Axonics reported $180.3 million in revenue in fiscal 2021, compared to $707,000 in fiscal 2018.

The company topped last year’s version of the list. Axonics develops novel products for adults with bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy-to-use, safe, clinically effective therapy. The compa…

5 top ophthalmic device innovations you need to know

Innovation finds its way into all areas of medtech, and ophthalmic treatments represent another burgeoning space. [Image from Pixabay]It may not be a new wave, but medtech companies continue to improve upon technologies for the human eye.

Implants, lenses and more comprise the space’s latest innovations, with a number of companies finding new ways to fix old problems.

Here are five innovations in ophthalmic technology that have caught the eye of editors here at MassDevice:

Johnson & Johnson Vision’s drug-eluting contact lens

Johnson & Johnson Vision (NYSE:JNJ) Director of Clinica Science Dr. Brian Pall told MassDevice earlier this year that researchers considered the notion of delivering medication through contact lenses as far back as the 1960s.

[Image from Johnson & Johnson Vision]It took until 2022 for that vision to come to fruition. In March, Johnson & Johnson announced that the FDA approved its Acuvue Theravision with K…

Data supports Sight Sciences’ Omni surgical system for glaucoma

[Image from Sight Sciences]Sight Sciences (Nasdaq:SGHT) announced today that 36-month data supports the use of its Omni surgical system.

Data from the three-year post-surgery follow-up demonstrates that the Omni surgical system delivers safe, consistent and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basement.

Menlo Park, California-based Sight Sciences evaluated the Omni system in canaloplasty followed by trabeculectomy, with the system achieving a mean reduction in intraocular pressure (IOP) of at least 20 percent for all 26 patients (38 eyes) at 36 months follow-up.

Post-operative IOP and medication use reduction at 12 months remained consistent over the three years, suggesting robust, durable effectiveness when used as a standalone intervention in either phakic or pseudophakic eyes, according to a news release.

Sight Sciences received reports of a “minimal number” of adverse events, all of which we…

Sight Sciences touts positive study results of dry eye treatment device

Sight Sciences today announced positive results from a clinical trial of its TearCare wearable eyelid technology.

The Olympia study was a prospective, randomized multicenter trial that enrolled 235 dry eye patients across 10 sites in the U.S. The goal was to demonstrate the safety and effectiveness of a single TearCare procedure compared to the LipiFlow Thermal Pulsation System in treating signs and symptoms of dry eye disease.

Study results showed that a single TearCare treatment was able to safely and effectively achieve clinically meaningful improvements in all signs and symptoms of dry eye disease. Improvement in signs included tear break up time, meibomian gland secretion score and corneal and conjunctival staining. Symptom improvement included ocular surface disease index score, symptom assessment in dry eyes score and eye dryness score.

The company reported a significantly greater proportion of TearCare patients that had clinically meaning…